Global Clomiphene Citrate Market, by Indication (PCOS, Secondary Amenorrhea, Psychogenic Amenorrhea, Amenorrhea Galactorrhea Syndrome, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 10.02 million in 2020 and is expected to exhibit a CAGR of 5.4% during the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.

Clomiphene Citrate Market - Impact of Coronavirus (Covid-19) Pandemic

COVID-19 is expected to have a moderate impact on the clomiphene citrate market, owing to issues in transportation of drugs and medical devices. For instance, due to lockdown, many countries such as Italy, Spain, U.K., the U.S., India, and others are facing issues in terms of demand & supply and transportation of clomiphene citrate medicines in their countries. Thus, COVID-19 pandemic has affected the economy in three main ways; 1) by directly affecting the production and demand; 2) by creating disruptions in distribution channels; and 3) through its financial impact on companies and financial markets. Supply chain and manufacturing activities in India and China have been disrupted due to the global lockdowns, while countries such as Thailand, Indonesia, Singapore, and others are facing problems with regards to transportation of drugs.

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/clomiphene-citrate-market-4140

Furthermore, the increasing research and development, and agreements among key players are major factors that are expected to drive growth of the clomiphene citrate market during the forecast period.

The development of novel isomers of clomiphene citrate by leading market players is expected to create a lucrative environment for other manufacturers to develop such isomers of clomiphene citrate for treatment of male infertility. The two isomers of clomiphene citrate are enclomiphene citrate and zuclomiphene citrate. These are isomers of each other. For instance, in September 2018, Veru Inc. started a clinical trial with the drug candidate Veru-944 (Zuclomiphene citrate) for the treatment of prostate cancer. This clinical trial is in phase 2 with 120 men with advanced prostate cancer. This phase 2 clinical trial was completed by July 30, 2020.

The increasing research and development of clomiphene citrate by different research institutes is expected to contribute significantly to the clomiphene citrate market growth. For instance, in February 2019, University of Iowa conducted a clinical trial to study the combined treatment of Letrozole and Clomid in women with infertility and PCOS. Results showed that women who received both Letrozole and Clomid had higher ovulation rates when compared to those who took Letrozole alone (77% vs. 43%).

Browse 26 Market Data Tables and 29 Figures spread through 166 Pages and in-depth TOC on Clomiphene Citrate Market, by Indication (PCOS, Secondary Amenorrhea, Psychogenic Amenorrhea, Amenorrhea Galactorrhea Syndrome, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Forecast to 2027"

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/4140

Several market players are focused on inorganic growth strategies such as definitive agreements to expand their product portfolio and gain maximum share in the market. For instance, in May 2015, Par Pharmaceutical Holdings, Inc. and Endo International plc entered into a definitive agreement, under which Endo acquired privately-held Par from TPG (an American investment company) in a transaction valued at US$ 8.05 billion. The combination of the two companies i.e., Endo International plc and Par Pharmaceutical Holdings, Inc., is expected to create a specialty pharmaceutical company with a generics business. Furthermore, Par Pharmaceuticals is a part of the Patient Assistance Program, which provides medicines free of cost to patients who cannot afford the medicines manufactured by Par Pharmaceuticals for their treatment.

Key Takeaways of the Clomiphene Citrate Market:

The clomiphene citrate market is expected to exhibit a CAGR of 5.4% during the forecast period (2020-2027), owing to increasing research and development activities, clinical trials, and definitive agreements by key players in the market

Among indication, the PCOS segment is expected to hold a major revenue share in 2027, owing to increasing prevalence of PCOS, worldwide. For instance, according to the Centers for Disease Control and Prevention, PCOS is one of the most common causes of female infertility, affecting 6% to 12% (as many as 5 million) of women of reproductive age in the U.S in 2019. Furthermore, as per the same source, in some European studies, the prevalence of PCOS has been reported to be 6.5% to 8% in 2019 in the U.K.

Major players operating in the clomiphene citrate market include Sanofi S.A., Par Pharmaceutical, Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., Cipla Inc., Unichem Laboratories Ltd., Emcure Pharmaceuticals Ltd., Serum Institute of India Pvt. Ltd., Incepta Pharmaceuticals Ltd., and Shanghai Trifecta Pharma Co. Ltd.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/4140

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
mailto:[email protected]
U.S. Office:
Name: Mr. Shah
Coherent Market Insights 1001 4th Ave,
# 3200 Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737